Comparative Safety Signals for Melanoma Checkpoint Inhibitors Across Trials and FAERS
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Chen Y, Liang X, Chen X, et al.
Jul 29, 2026 · Published in: Health Science Reports
Immune checkpoint inhibitors in melanoma: safety profiles unveiled.
Oral Aprepitant Versus IV Fosaprepitant: Comparable CINV Control in Practice
Analysis Oncology Pharmacy Confirmatory Grade: Low
Ünlü B, Demir H, Davarcı SE, et al.
Jul 27, 2026 · Published in: Current Oncology (Toronto, Ont.)
Aprepitant and fosaprepitant are equally effective in real-world chemotherapy settings.
Bevacizumab Adds Survival in Elderly Driver-Negative Lung Adenocarcinoma
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Li S, Wang S, Cao R
Jul 25, 2026 · Published in: Medicine
Also in Geriatrics
Bevacizumab boosts survival in elderly lung cancer patients.
IO Plus TKI Shows No Survival Gain in Favourable-Risk RCC
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Valdés A, González-Montero J, Rojas C, et al.
Jul 25, 2026 · Published in: Oncology Research
Combination therapy may not benefit favourable-risk metastatic renal cell carcinoma patients.
Venetoclax TDM Reduces Toxicity Risk in Posaconazole-Treated AML Patients
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Sani B, Cignetti A, Leporati M, et al.
Jul 25, 2026 · Published in: Oncology Research
Also in Pharmacokinetics / TDM
Venetoclax levels spike with posaconazole: TDM is essential.
Daraxonrasib Halves Death Risk in Previously Treated Pancreatic Cancer
Analysis Oncology Pharmacy Practice-changing Grade: Moderate
O'Reilly EM, Wainberg ZA, Hendifar AE, et al.
Jul 23, 2026 · Published in: The New England Journal of Medicine
Daraxonrasib doubles survival in metastatic pancreatic cancer.
Neoadjuvant Chemotherapy Enables Pregnancy Continuation in Cervical Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Kang OJ, Koh JH, Lee SW, et al.
Jul 23, 2026 · Published in: The Journal of Obstetrics and Gynaecology Research
Also in Women's Health / Reproductive
Innovative cervical cancer treatment preserves pregnancy in cancer patients.
Immunotherapy May Enable Safe Axillary De-escalation in Node-Positive TNBC
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Li Z, Qu Z, Pei S, et al.
Jul 23, 2026 · Published in: Frontiers in Immunology
Chemo-immunotherapy may enable less invasive breast cancer surgeries.
Two-Year Lenalidomide Maintenance Matches Indefinite Therapy in Standard-Risk Myeloma
Analysis Oncology Pharmacy Practice-changing Grade: Moderate
Kumar S, Jacobus S, Cohen A, et al.
Jul 16, 2026 · Published in: N Engl J Med
Two-year lenalidomide is as effective as indefinite therapy in multiple myeloma.
CNS Hemorrhage Signal With MAPK-Pathway Inhibitors Demands Risk Stratification
Analysis Neurology / Neuropharmacology Hypothesis-generating Grade: Low
Damodharan S, Calderon A, Abdelbaki MS
Jul 15, 2026 · Published in: Journal of Neuro-oncology
Also in Oncology
MAPK-pathway inhibitors pose a serious intracranial hemorrhage risk in neuro-oncology.
Navigating Three BCMA-Targeted Modalities and Their Optimal Sequencing in Myeloma
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Mihara K, Miyama T
Jul 15, 2026 · Published in: International Journal of Hematology
BCMA-targeted therapies revolutionize multiple myeloma care, balancing efficacy with unique toxicities.
Adjuvant TACE and Lenvatinib-Tislelizumab Show Comparable Post-Resection Benefit
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Feng X, Ao Y, Wang L, et al.
Jul 14, 2026 · Published in: Frontiers in Immunology
Adjuvant therapies improve survival in high-risk liver cancer patients.
Transporters and CYP3A4 Shape Daraxonrasib Brain and Plasma Exposure
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Arguedas D, Bui V, Law T, et al.
Jul 8, 2026 · Published in: Pharmacological Research
Also in Pharmacokinetics / TDM
Transporter interactions may challenge daraxonrasib's effectiveness against brain metastases.
Immune Checkpoint Inhibitors Redefine First-Line Cholangiocarcinoma Therapy
Analysis Oncology Pharmacy Confirmatory Grade: Moderate
Nisa FU, Ali M, Khan T, et al.
Jul 6, 2026 · Published in: Journal of the Egyptian National Cancer Institute
Immune checkpoint inhibitors redefine advanced cholangiocarcinoma treatment.
Targeted Therapy Evolution: From Kinase Inhibitors to Protein Degraders
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Wang Y, Tang SC
Jun 27, 2026 · Published in: Critical Reviews in Oncology/hematology
Targeted cancer therapies revolutionize personalized oncology treatment.